BSE filing, NSE: LAURLOR. Summary written from the filing by ALFA Finder's alert engine.
Kimia Biosciences Ltd: key numbers
- Share price
- ₹30.25
- Market cap
- ₹143.1 Cr
- Revenue (annual)
- ₹114.9 Cr
- Net profit (annual)
- ₹7.43 Cr
- P/E (TTM)
- 19.9×Sector 46.1×
- Promoter holding
- 74.94%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kimia Biosciences Ltd
All →Kimia Biosciences Other Announcement
Kimia Biosciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Kimia Biosciences Management Change
Kimia Biosciences Limited announced the re-appointment of Mr. Sameer Goel as Executive Director and changes in designation for three other directors on the board.
Kimia Biosciences Annual General Meeting
Kimia Biosciences Ltd filed the proceedings of its 33rd Annual General Meeting held on September 28, 2026, where shareholders considered various ordinary and special resolutions.
Kimia Biosciences Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended March 31, 2026.
Kimia Biosciences Annual General Meeting
Kimia Biosciences Limited has submitted its notice for the 33rd Annual General Meeting scheduled for September 28, 2026, along with the Annual Report for FY 2025-26.
Kimia Biosciences Q1 FY27 Results: Net Profit ₹0.4 Cr, Down 33.3% YoY
Kimia Biosciences Ltd reported revenue from operations of ₹20.7 Cr (-12.3% YoY) and net profit of ₹0.4 Cr (-33.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.4 Cr · -33.3% YoY
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.